With a variety of new (and expensive) therapies in the pipeline for 2023, it is understandable that the industry is feeling anxiety over the rise of high-cost drugs. However, there is not one-size-fits all solution. Industry stakeholders must consider and respond differently to each drug type.
In this episode, host Rachel (Rae) Woods invites Advisory Board pharmacy experts Gina Lohr and Chloe Bakst to discuss how industry stakeholders are thinking about different high-cost drugs and how they can prepare for the future.
Links:
Create your free account to access 1 resource, including the latest research and webinars.
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
You've reached your limit of free insights
Never miss out on the latest innovative health care content tailored to you.
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Never miss out on the latest innovative health care content tailored to you.
This is for members only. Learn more.
Never miss out on the latest innovative health care content tailored to you.